Solel Partners LP sold 624,800 shares of Brightstar Lottery, an estimated $10.18 million trade based on average closing prices for the quarter.
The quarter-end position value fell by $15.73 million, reflecting both trading activity and market price changes.
After the trade, the fund held 2,795,324 shares valued at $43.27 million.
The position now represents approximately 7% of 13F AUM.
On February 17, 2026, Solel Partners disclosed in a U.S. Securities and Exchange Commission (SEC) filing that it sold 624,800 shares of Brightstar Lottery (NYSE:BRSL) in the fourth quarter, an estimated $10.18 million transaction based on quarterly average pricing.
According to a February 17, 2026, SEC filing, Solel Partners LP reduced its stake in Brightstar Lottery (NYSE:BRSL) by 624,800 shares during the fourth quarter. The estimated transaction value was $10.18 million, calculated using the average closing price from October 1 to December 31, 2025. At quarter-end, the remaining position was valued at $43.27 million, a $15.73 million decrease from the prior period, reflecting both the share sale and changes in market price.
| Metric | Value |
|---|---|
| Market Capitalization | $2.54 billion |
| Revenue (TTM) | $2.49 billion |
| Net Income (TTM) | $304.00 million |
Brightstar Lottery is a leading global lottery technology and services provider. The company’s strategic focus on regulated lottery markets and divestiture of non-core gaming assets positions it as a specialized operator with strong recurring revenue streams. Its expertise and proprietary technology underpin a competitive advantage in serving government and licensed lottery customers across multiple jurisdictions.
Brightstar just posted a solid third quarter, with revenue up 7% to $629 million and adjusted EBITDA climbing 11% to $294 million, fueled by 7.9% same-store sales growth and jackpot strength. Meanwhile, income from continuing operations swung to $95 million from a loss a year ago, and net debt leverage sits at a manageable 2.3x.
Nevertheless, the stock is down 26% over the past year, and Solel just reduced its position to roughly 7% of assets. That trim is notable, but context matters. This portfolio still leans heavily into healthcare and financial names like UNH, SYF, and CVS, with Brightstar sitting alongside digital marketing exposure in BRZE. In other words, this is not a wholesale rejection of the lottery thesis, just resizing within a diversified book.
Brightstar’s $4 billion IGT Gaming divestiture, $978 million returned to shareholders year to date, and new 2028 targets of $2.75 billion in revenue and $1.3 billion in EBITDA point to a refocused, cash-generative pure play. Long-term investors should focus on recurring lottery cash flows, disciplined leverage, and execution against those medium term targets rather than short term trading signals.
Before you buy stock in Brightstar Lottery Plc, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Brightstar Lottery Plc wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $415,256!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,151,865!*
Now, it’s worth noting Stock Advisor’s total average return is 892% — a market-crushing outperformance compared to 194% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.
See the 10 stocks »
*Stock Advisor returns as of February 20, 2026.
Synchrony Financial is an advertising partner of Motley Fool Money. Jonathan Ponciano has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Braze. The Motley Fool recommends CVS Health and UnitedHealth Group. The Motley Fool has a disclosure policy.